Looks like they had to rip out the $ amount and the BP concerned.
I find the ASX has gone into overkill on many companies I hold on release compliance.
Key
• The Agreement is significant to the ATCOR core business in that the total revenue to be received
over the length of trial is anticipated to be twice the FY22 revenues for the entire business.
Whilst the revenue attribution across the trial’s duration is yet to be determined, approximately
40% of the cashflow from the trial is expected to be received in FY23, and the balance to be
received over the rest of the trials expected duration of ~30 months.
Ann: CardieX Announces Significant New Clinical Trial Agreement, page-2
Add CDX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.4¢ |
Change
0.001(1.89%) |
Mkt cap ! $15.88M | |||
| Open | High | Low | Value | Volume |
| 5.3¢ | 5.5¢ | 5.2¢ | $31.07K | 586.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 5.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.4¢ | 149188 | 1 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
5.4¢ |
Change
0.001 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 5.3¢ | 5.4¢ | 5.3¢ | 56887 | ||
| Last updated 11.47am 03/05/2024 ? | |||||
| CDX (ASX) Chart |